---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-018396"
form_type: "8-K"
ticker: "INMB"
cik: "0001711754"
company_name: "Inmune Bio, Inc."
filed_at: "2026-02-19T23:59:59+00:00"
generated_at: "2026-05-16T01:47:26.995813+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "medium"
source: SEC EDGAR
---

# INmune Bio to host Feb 26 webinar on new CORDStrom Phase III data for RDEB

## Summary
- Webinar on February 26, 2026 at 1:00 PM ET to present new MissionEB Phase III data for CORDStrom in RDEB.
- Focus: systemic disease-modifying therapy beyond topical care, including EBDASI scores, weight gain, pain/itch reduction, and quality of life.
- Featured speakers: Dr. Anna Martinez (Principal Investigator) and CSO Prof. Mark Lowdell.
- CORDStrom is a patented allogeneic hucMSC cell medicine positioned for inflammatory/autoimmune diseases.

## SEC filing metadata
- accession: 0001213900-26-018396
- form_type: 8-K
- ticker: INMB
- cik: 0001711754
- company_name: Inmune Bio, Inc.
- filed_at: 2026-02-19T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: medium
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711754/000121390026018396/0001213900-26-018396-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711754/000121390026018396/ea0277663-8k_inmune.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-018396
- JSON: https://secwatch.observer/filing/0001213900-26-018396.json
- Plain text: https://secwatch.observer/filing/0001213900-26-018396.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.